Telix Pharmaceuticals Limited Stock Performance
| TLPPF Stock | USD 16.00 0.10 0.63% |
The entity has a beta of 0.5, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Telix Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Telix Pharmaceuticals is expected to be smaller as well. At this point, Telix Pharmaceuticals has a negative expected return of -0.23%. Please make sure to validate Telix Pharmaceuticals' jensen alpha, skewness, as well as the relationship between the Skewness and day typical price , to decide if Telix Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Telix Pharmaceuticals Limited has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in August 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
| Begin Period Cash Flow | 77.9 M | |
| Total Cashflows From Investing Activities | -2.7 M |
Telix |
Telix Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,925 in Telix Pharmaceuticals Limited on April 25, 2025 and sell it today you would lose (325.00) from holding Telix Pharmaceuticals Limited or give up 16.88% of portfolio value over 90 days. Telix Pharmaceuticals Limited is currently producing negative expected returns and takes up 3.7658% volatility of returns over 90 trading days. Put another way, 33% of traded pink sheets are less volatile than Telix, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Telix Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Telix Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Telix Pharmaceuticals Limited, and traders can use it to determine the average amount a Telix Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0612
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | TLPPF |
Estimated Market Risk
| 3.77 actual daily | 33 67% of assets are more volatile |
Expected Return
| -0.23 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.06 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Telix Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Telix Pharmaceuticals by adding Telix Pharmaceuticals to a well-diversified portfolio.
Telix Pharmaceuticals Fundamentals Growth
Telix Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Telix Pharmaceuticals, and Telix Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Telix Pink Sheet performance.
| Return On Equity | -1.55 | |||
| Return On Asset | -0.41 | |||
| Operating Margin | (3.95) % | |||
| Current Valuation | 1.39 B | |||
| Shares Outstanding | 317.02 M | |||
| Price To Book | 21.16 X | |||
| Price To Sales | 52.21 X | |||
| Revenue | 4.9 M | |||
| EBITDA | (70.07 M) | |||
| Cash And Equivalents | 122.61 M | |||
| Cash Per Share | 0.39 X | |||
| Total Debt | 2.57 M | |||
| Debt To Equity | 0.02 % | |||
| Book Value Per Share | 0.34 X | |||
| Cash Flow From Operations | (59.33 M) | |||
| Earnings Per Share | (0.20) X | |||
| Total Asset | 109.81 M | |||
About Telix Pharmaceuticals Performance
By analyzing Telix Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Telix Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Telix Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Telix Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company was founded in 2015 and is headquartered in North Melbourne, Australia. Telix Pharmaceuticals operates under Biotechnology classification in the United States and is traded on OTC Exchange.Things to note about Telix Pharmaceuticals performance evaluation
Checking the ongoing alerts about Telix Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Telix Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Telix Pharmaceuticals generated a negative expected return over the last 90 days | |
| Telix Pharmaceuticals has high historical volatility and very poor performance | |
| Telix Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 4.9 M. Net Loss for the year was (80.51 M) with profit before overhead, payroll, taxes, and interest of 5.05 M. | |
| Telix Pharmaceuticals Limited has accumulated about 122.61 M in cash with (59.33 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.39. | |
| Roughly 28.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Telix Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Telix Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Telix Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Telix Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Telix Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Telix Pharmaceuticals' pink sheet. These opinions can provide insight into Telix Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Telix Pink Sheet analysis
When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |